Taizhou Xingputai Biopharmaceutical Co., LTD., based on the key research and development direction of peptide drugs planned by "Made in China 2025" and the strategic deployment of the "13th Five-Year Plan" biological industry Development Plan, is committed to providing integrated research and development and production services for global customers of innovative peptide drugs, and developing innovative peptide drugs with independent intellectual property rights. The company has built a large-scale medicinal polypeptide API project with an annual output of 3000kg in Taixing Economic Development Zone, covering an area of 120 mu. By integrating the world's top new drug discovery technology and ...
